Of the 4,500 respondents to the survey, 88% reported “a similar or better feeling” than their reaction to the previous dose, with 31% saying they had localized effects like pain or swelling in the area of injection, according to a statement from Clalit Health Services late Sunday.
About 15% of people had other symptoms like tiredness, muscle aches or fever. Less than 1% reported difficulty breathing or chest pains.
Israel became the first country in the world to disseminate booster shots widely in a bid to quell a surge in new cases. The U.S. hasn’t yet sanctioned the use of third doses, although Pfizer said it plans to meet with U.S. regulators for authorization. About 500,000 Israelis have received the third dose so far.
Clalit said the results of the study, involving people vaccinated over July 30 and Aug. 1, still needed to be analyzed carefully given the short testing period. Some people who received boosters may have been suffering from significant side effects that precluded their participation in the survey, it said.
BioNTech’s American depositary receipts climbed as much as 11% on Monday after the company raised its forecast for this year’s Covid-19 vaccine sales to 15.9 billion euros ($18.7 billion) and said it is pushing forward plans to test its messenger RNA technology in cancer. (Bloomberg)